Anteris Technologies Global AVR
- Market cap
- $572.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- a sliver of sales
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.2M
- −10% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −15.4%
Anteris Technologies Global's trailing earnings are negative, so it has no PE. Revenue was $2.2M over the last twelve months, down 10% on a year earlier.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $766K | $632K | $769K | $536K | $556K−27% | $618K−2% | $429K−44% | $310K−42% | $494K−11% | $1M+63% | |
| Cost of revenue | $473K | $312K | $443K | $208K | $207K−56% | $148K−53% | $123K−72% | $91K−56% | $114K−45% | $233K+57% |
| Gross profit | $293K | $320K | $326K | $328K | $349K+19% | $470K+47% | $306K−6% | $219K−33% | $380K+9% | $776K+65% |
| R&D | $11.6M | $12.6M | $13.9M | $13.3M | $16.5M+42% | $16.3M+29% | $16.8M+21% | $19.5M+47% | $17.5M+6% | $23.4M+43% |
| SG&A | $6.5M | $6.2M | $7M | $8.5M | $5.7M−13% | $5M−19% | $5.8M−17% | $9.7M+13% | $6.9M+22% | $8.4M+68% |
| −$17.8M | −$18.5M | −$20.6M | −$21.5M | −$21.8M+23% | −$20.9M+13% | −$22.3M+8% | −$29M+35% | −$24M+10% | −$31M+48% | |
| Interest expense | $17K | $11K | $11K | $8K | $26K+53% | $22K+100% | $15K+36% | $10K+25% | $27K+4% | $131K+496% |
| Pre-tax income | −$16.2M | −$18.8M | −$21.8M | −$19.2M | −$21.9M+36% | −$21.1M+12% | −$22.2M+2% | −$29M+51% | −$22.4M+2% | −$28.8M+37% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $492K | $0 | |
| Net income | −$16.4M | −$18.7M | −$21.9M | −$19.4M | −$21.9M+34% | −$20.8M+11% | −$22.2M+2% | −$29.2M+51% | −$23M+5% | −$29.1M+40% |
| −$0.91 | −$0.98 | −$1.07 | −$0.82 | −$0.61−33% | −$0.58−41% | −$0.62−42% | −$0.74−10% | −$0.28−54% | −$0.30−48% | |
| 17.9M | 19M | 20.5M | 23.6M | 36M+101% | 36.1M+90% | 36.1M+76% | 39.5M+68% | 83M+131% | 97.3M+170% |
Gross profit: 10 periods, Q1 FY24 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Anteris Technologies Global's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AVRAnteris Technologies Global | $572.1M | n/m | n/a | n/m | −10% | n/m | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| Peer median | $635.9M | 28.3× | 31.5× | 1.9× | +4% | 6.5% |
More on Anteris Technologies Global
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .